Reviewing INDs as They Are Prepared: FDA’s TrialBlazer Pilot Targets First-in-Human Dosing

Delays in moving a new drug from the laboratory to the first trial participant often occur in more than just a single application. The U.S. Food and Drug Administration (FDA) is advancing a rapid investigational new drug (IND) pilot concept called TrialBlazer, seeking to separate preparatory procedures that traditionally take place in sequence and shorten the time from candidate drug identification to first-in-human trials.

Under the FDA’s proposed voluntary framework, academic medical centers, healthcare networks, contract research organizations, regulatory consultants, and others may apply to become “Qualified Research Institutions” (QRIs). These institutions would help applicants prepare and conduct an initial review of pharmacology and toxicology information, clinical protocols, and chemistry, manufacturing, and controls (CMC) data, with the aim of identifying gaps before formal submission and improving the completeness of Phase 1 INDs.

At the core of the pilot is a rolling submission platform. Completed data modules could be submitted to the FDA for review without waiting for the entire IND to be ready; however, the statutory 30-day review period would not begin until the final module is received. If major issues have already been addressed earlier in the process, the FDA may notify the applicant before the 30 days have elapsed that the trial may proceed. This could also reduce requests for additional information or clinical holds due to insufficient data.

QRIs would not replace the regulator. Their opinions would be advisory only, while applicants would remain responsible for the IND’s content and associated obligations. The FDA would also retain its full authority to determine whether a study may begin, issue clinical hold orders, disqualify investigators, and conduct inspections. The arrangement seeks to draw on external expertise while deliberately maintaining clear lines of responsibility for drug safety and participant protection.

Faster Review Does Not Mean Earlier Patient Enrollment

The more difficult challenges may lie outside the FDA. TrialBlazer also seeks to test whether institutional review board (IRB) review, trial-site contracting, and site activation can proceed alongside IND preparation and review. Clinical trial operations experts have noted that IRB approval and contract negotiations combined can add as much as 13 months, while site activation often takes more than 160 days. By comparison, the standard 30-day IND review period may not be the primary bottleneck to first dosing.

Accordingly, if the pilot measures only how quickly an IND is cleared, it may overestimate the actual impact. Metrics that better reflect the reform’s value include the total time from candidate drug identification to dosing of the first participant, as well as whether participating institutions can consistently complete site activation and recruitment. Questions also remain about how QRIs will be designated, the extent to which the FDA can rely on third-party assessments, how conflicts of interest will be managed, and whether companies with fewer resources can participate fairly.

The FDA proposed the program in June and solicited public comments. At this stage, it remains a pilot design rather than an expedited pathway with established results. Whether it can keep early-stage clinical research in the United States will ultimately depend not only on how much faster the review process becomes, but also on whether research institutions, ethics reviews, contracting, and enrollment capabilities can keep pace.